Join us in Vienna for a comprehensive exploration of translational heart failure research. This prestigious event brings together researchers, clinicians, and industry leaders to discuss the latest advancements in understanding and treating heart failure. Key topics include novel therapeutic targets, patient care innovations, and interdisciplinary collaborations. Our team will share insights from our latest research and engage in discussions on overcoming challenges in heart failure management. Schedule a meeting with us to exchange ideas and explore collaborative opportunities.
Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1
March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
